Sign in or create an account to add this stock to your watchlist.
About Pieris Pharmaceuticals (NASDAQ:PIRS)
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is involved in developing PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases; PRS-332, a bispecific anticalin-antibody fusion protein that is in preclinical evaluation stage for oncology diseases; PRS-080 that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate, which is in Phase I clinical trial that binds to the IL- 4Ra receptor for the treatment of asthma and other inflammatory diseases, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., Sanofi Group, Allergan Sales, LLC, Allergan, Inc., and Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PIRS
CUSIPN/A
Phone857-246-8998
Debt
Debt-to-Equity RatioN/A
Current Ratio3.03
Quick Ratio3.03
Price-To-Earnings
Trailing P/E Ratio-14.78
Forward P/E Ratio-12.31
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.27 million
Price / Sales12.62
Cash FlowN/A
Price / CashN/A
Book Value$0.26 per share
Price / Book22.73
Profitability
EPS (Most Recent Fiscal Year)($0.40)
Net Income$-17,640,000.00
Net Margins-65.40%
Return on Equity-96.56%
Return on Assets-15.25%
Miscellaneous
Employees68
Outstanding Shares53,970,000
Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions
What is Pieris Pharmaceuticals' stock symbol?
Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."
How were Pieris Pharmaceuticals' earnings last quarter?
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.15. The biotechnology company had revenue of $4.15 million for the quarter, compared to analyst estimates of $11.39 million. Pieris Pharmaceuticals had a negative return on equity of 96.56% and a negative net margin of 65.40%. View Pieris Pharmaceuticals' Earnings History.
What price target have analysts set for PIRS?
6 equities research analysts have issued 12 month price targets for Pieris Pharmaceuticals' shares. Their forecasts range from $9.00 to $13.00. On average, they expect Pieris Pharmaceuticals' stock price to reach $11.50 in the next twelve months. View Analyst Ratings for Pieris Pharmaceuticals.
Who are some of Pieris Pharmaceuticals' key competitors?
Some companies that are related to Pieris Pharmaceuticals include National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), Viralytics (VRACY), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International (DYAI), Vitality Biopharma (VBIO), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Protalex (PRTX), Bioanalytical Systems (BASI) and U.S. Stem Cell (USRM).
Who are Pieris Pharmaceuticals' key executives?
Pieris Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen S. Yoder, CEO, Pres & Director (Age 42)
- Dr. Allan Reine, Sr. VP, CFO & Treasurer (Age 43)
- Dr. Louis A. Matis, Sr. VP & Chief Devel. Officer (Age 67)
- Mr. Claus Schalper MBA, Co-Founder & Sr. Advisor
- Mr. Ahmed Mousa, VP of Licensing, IP & Legal Affairs and Corp. Compliance Officer
Has Pieris Pharmaceuticals been receiving favorable news coverage?
Media headlines about PIRS stock have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Pieris Pharmaceuticals earned a media sentiment score of 0.07 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 47.10 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Pieris Pharmaceuticals' major shareholders?
Pieris Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BVF Inc. IL (6.67%), Millennium Management LLC (3.38%), BlackRock Inc. (3.34%), Omega Fund Management LLC (1.45%), Prosight Management LP (1.05%) and Northern Trust Corp (0.66%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, Darlene M Deptula-Hicks, James A Geraghty, Louis Matis, Orbimed Advisors Llc and Stephen S Yoder. View Institutional Ownership Trends for Pieris Pharmaceuticals.
Which major investors are selling Pieris Pharmaceuticals stock?
Which major investors are buying Pieris Pharmaceuticals stock?
PIRS stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, BVF Inc. IL, Prosight Management LP, BlackRock Inc., Allianz Asset Management GmbH, Wedge Capital Management L L P NC, Platinum Investment Management Ltd. and Baird Financial Group Inc.. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine, Darlene M Deptula-Hicks, James A Geraghty, Louis Matis and Stephen S Yoder. View Insider Buying and Selling for Pieris Pharmaceuticals.
How do I buy shares of Pieris Pharmaceuticals?
Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pieris Pharmaceuticals' stock price today?
One share of PIRS stock can currently be purchased for approximately $5.91.
How big of a company is Pieris Pharmaceuticals?
Pieris Pharmaceuticals has a market capitalization of $319.53 million and generates $25.27 million in revenue each year. The biotechnology company earns $-17,640,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Pieris Pharmaceuticals employs 68 workers across the globe.
How can I contact Pieris Pharmaceuticals?
Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]
MarketBeat Community Rating for Pieris Pharmaceuticals (PIRS)
MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe PIRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PIRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pieris Pharmaceuticals (NASDAQ:PIRS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Pieris Pharmaceuticals in the last 12 months. Their average twelve-month price target is $11.50, suggesting that the stock has a possible upside of 94.59%. The high price target for PIRS is $13.00 and the low price target for PIRS is $9.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $11.50 | $11.50 | $10.00 | $9.00 |
| Price Target Upside: | 94.59% upside | 61.97% upside | 25.16% upside | 64.53% upside |
Pieris Pharmaceuticals (NASDAQ:PIRS) Consensus Price Target History
Pieris Pharmaceuticals (NASDAQ:PIRS) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Pieris Pharmaceuticals (NASDAQ:PIRS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Pieris Pharmaceuticals (NASDAQ PIRS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.05%
Institutional Ownership Percentage: 62.85%
Pieris Pharmaceuticals (NASDAQ PIRS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/15/2018 | James A Geraghty | Director | Buy | 10,000 | $5.75 | $57,500.00 | 20,000 |  |
| 4/30/2018 | Orbimed Advisors Llc | Insider | Sell | 1,000,000 | $6.35 | $6,350,000.00 | | |
| 2/13/2018 | Orbimed Advisors Llc | Major Shareholder | Sell | 7,897 | $8.98 | $70,915.06 | | |
| 1/3/2018 | Orbimed Advisors Llc | Major Shareholder | Sell | 1,709,620 | $7.35 | $12,565,707.00 | | |
| 12/18/2017 | Orbimed Advisors Llc | Major Shareholder | Sell | 147,635 | $5.70 | $841,519.50 | | |
| 8/17/2017 | Allan Reine | Insider | Buy | 65,000 | $4.82 | $313,300.00 | 45,000 | |
| 8/17/2017 | James A Geraghty | Director | Buy | 10,000 | $4.82 | $48,200.00 | 10,000 | |
| 6/14/2016 | Louis Matis | SVP | Buy | 10,000 | $1.70 | $17,000.00 | 2,085 | |
| 6/13/2016 | Darlene M Deptula-Hicks | CFO | Buy | 5,000 | $1.66 | $8,300.00 | 5,000 | |
| 6/13/2016 | Stephen S Yoder | CEO | Buy | 6,000 | $1.68 | $10,080.00 | 6,000 | |
(Data available from 1/1/2013 forward)
Pieris Pharmaceuticals (NASDAQ PIRS) News Headlines
| Source: |
|
Pieris Pharmaceuticals (NASDAQ:PIRS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Pieris Pharmaceuticals (NASDAQ:PIRS) Income Statement, Balance Sheet and Cash Flow Statement
Pieris Pharmaceuticals (NASDAQ PIRS) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
